SI-BONE, Inc. (SIBN)

SI-BONE's stock has been influenced by several key events over the past six months. In November 2025, the company reported strong Q3 financial results. In January 2026, preliminary revenue for Q4 and full year 2025 was announced, followed by a stock price decline. In February 2026, record financial results for Q4 and full year 2025 were reported, along with 2026 guidance and FDA clearance for iFuse INTRA Ti™ implant. In April 2026, record worldwide revenue for 2025 was reported, a strategic distribution agreement with Smith+Nephew was entered, Medicare reimbursement increased, and BlackRock Inc. reported ownership. In May 2026, the company announced it would report Q1 2026 financial results and present at a healthcare conference, with some stock fluctuations occurring.

SI-BONE's products and services experience normal demand seasonality, with a slight sequential revenue decline anticipated between the second and third quarters. The fourth quarter is traditionally the company's largest in terms of revenue. The company is capitalizing on industry trends such as the demand for minimally invasive procedures and the increasing utilization of advanced implant technologies.

SI-BONE, Inc. specializes in surgical treatments for sacropelvic disorders, focusing on minimally invasive surgical implant systems for sacroiliac joint surgery and related procedures. Their product portfolio includes patented titanium implants and instruments, such as the iFuse Implant System, applied across various conditions. The company emphasizes clinical evidence, with numerous peer-reviewed publications and randomized controlled trials.

SI-BONE is a global organization headquartered in Santa Clara, California, with a significant international presence including a European headquarters in Gallarate, Italy, and additional offices in Germany, France, and the UK. The company's products are commercialized in the United States and internationally.

SI-BONE's brand reputation is generally positive regarding its business focus and clinical evidence, recognized for pioneering minimally invasive SI joint surgery. There have been some discussions regarding the company's corporate policies. SI-BONE is rated as "Lower Risk" concerning political activism in corporate governance, but implements race and identity-based policies. It supports DEI within its business practices, but removed DEI training from its Sustainability Report in 2023 without public explanation. The company's Supplier Code of Conduct requires international vendors to include sexual orientation and gender identity in their nondiscrimination policy.

The majority ownership of SI-BONE, Inc. rests with institutional investors and mutual funds, holding concentrated stakes. Major institutional holders include BlackRock Inc., The Vanguard Group, Stephens Investment Management, and T. Rowe Price. Founders and directors also retain meaningful voting influence.